CPC C07K 16/2818 (2013.01) [A61K 33/243 (2019.01); A61P 35/00 (2018.01); A61K 45/06 (2013.01)] | 30 Claims |
1. A method of treating non-small cell lung cancer (NSCLC) or increasing the survival of a patient with NSCLC, comprising:
(a) selecting a patient with NSCLC, wherein the patient has tested negative for epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations, and ROS1 fusions; and
(b) administering to the patient one or more doses of platinum-based chemotherapy in combination with one or more doses of a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to PD-1, thereby treating NSCLC in the patient;
wherein the antibody or antigen-binding fragment thereof that binds specifically to PD-1 comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) of a heavy chain variable region (HCVR) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 3; HCDR2 comprises the amino acid sequence of SEQ ID NO: 4; HCDR3 comprises the amino acid sequence of SEQ ID NO: 5; LCDR1 comprises the amino acid sequence of SEQ ID NO: 6; LCDR2 comprises the amino acid sequence of SEQ ID NO: 7; and LCDR3 comprises the amino acid sequence of SEQ ID NO: 8.
|